Literature DB >> 17065629

In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Kaori Tanaka1, Hiroshige Mikamo, Ken'ichi Nakao, Kunitomo Watanabe.   

Abstract

The in vitro activity of DX-619, a new des-F(6) quinolone, against anaerobic bacteria was evaluated. DX-619 showed potent activity against Bacteroides, Prevotella, Fusobacterium, Micromonas, Actinomyces, and Clostridium spp., with MIC(50)s/MIC(90)s of </=0.03 to 0.25/</=0.03 to 1 microg/ml, respectively. DX-619 was also active against imipenem-resistant Bacteroides spp., with MIC(50)s/MIC(90)s of 0.25/1 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17065629      PMCID： PMC1635190          DOI： 10.1128/AAC.00639-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  R Schaumann; G Ackermann; B Pless; M C Claros; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

Authors:  Thomas J Louie
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

3.  Anaerobic infections in humans: an overview.

Authors:  S M Finegold
Journal:  Anaerobe       Date:  1995-02       Impact factor: 3.331

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  In vitro activity of gemifloxacin (SB 265805) against anaerobes.

Authors:  E J Goldstein; D M Citron; Y Warren; K Tyrrell; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

7.  Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.

Authors:  N Kato; H Kato; K Tanaka-Bandoh; K Watanabe; K Ueno
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

8.  Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.

Authors:  N Kato; H Kato; K Tanaka-Bando; K Watanabe; K Ueno
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

9.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262
View more
  2 in total

Review 1.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

2.  Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery.

Authors:  Elizabeth A Baldwin; Marina Walther-Antonio; Douglas J Creedon; Nicholas Chia; Allison M MacLean; Daryl M Gohl; Kenneth B Beckman; Jun Chen; Bryan White
Journal:  PeerJ       Date:  2015-11-26       Impact factor: 2.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.